{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:12:53Z","timestamp":1761606773957,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"am","delay-in-days":685,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","award":["13- 077"],"award-info":[{"award-number":["13- 077"]}],"id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009468","name":"Conseil R\u00e9gional Aquitaine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009468","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jchromb.2022.123411","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T16:44:50Z","timestamp":1659804290000},"page":"123411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Urine biomonitoring of occupational exposure to methotrexate using a highly sensitive UHPLC-MS\/MS method in MRM3 mode"],"prefix":"10.1016","volume":"1209","author":[{"given":"Antoine","family":"Villa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Tremolet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9atrice","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murielle","family":"Petit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Dascon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00e9mie","family":"Stanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Ducint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Titier-Debeaupuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Verdun-Esquer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Molimard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireille","family":"Canal-Raffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jchromb.2022.123411_b0005","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1007\/s11033-020-05481-9","article-title":"Molecular mechanism of action and pharmacokinetic properties of methotrexate","volume":"47","author":"Maksimovic","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.jchromb.2022.123411_b0010","unstructured":"FDA, Content and Format of Labeling for Human Prescription Drug and Biological Products\u00a0; Requirements for Pregnancy and Lactation Labeling, Food and Drug Administration, 2008."},{"key":"10.1016\/j.jchromb.2022.123411_b0015","first-page":"239","article-title":"FDA pregnancy risk categories and the CPS","volume":"56","author":"Law","year":"2010","journal-title":"Can. Fam. Physician"},{"key":"10.1016\/j.jchromb.2022.123411_b0020","unstructured":"NIOSH, NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, 2016."},{"issue":"10068","key":"10.1016\/j.jchromb.2022.123411_b0025","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(16)32127-4","article-title":"An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Warren","year":"2017","journal-title":"Lancet"},{"issue":"10068","key":"10.1016\/j.jchromb.2022.123411_b0030","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0140-6736(16)32574-0","article-title":"Should methotrexate remain the first-line drug for psoriasis?","volume":"389","author":"Gladman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jchromb.2022.123411_b0035","first-page":"46","article-title":"Systemic psoriasis therapies and comorbid disease in patients with psoriasis: a review of potential risks and benefits","volume":"12","author":"Mikhaylov","year":"2019","journal-title":"J. Clin. Aesthet. Dermatol."},{"issue":"7","key":"10.1016\/j.jchromb.2022.123411_b0040","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature","volume":"68","author":"Visser","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.jchromb.2022.123411_b0045","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jbspin.2011.01.010","article-title":"Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review","volume":"78","author":"Mouterde","year":"2011","journal-title":"Joint Bone Spine"},{"issue":"5","key":"10.1016\/j.jchromb.2022.123411_b0050","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/14740338.2019.1612874","article-title":"Safety of drugs used for the treatment of Crohn\u2019s disease","volume":"18","author":"Pudipeddi","year":"2019","journal-title":"Expert Opin Drug Saf."},{"issue":"6","key":"10.1016\/j.jchromb.2022.123411_b0055","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF00383251","article-title":"Biological and environmental monitoring of occupational exposure of pharmaceutical plant workers to methotrexate","volume":"65","author":"Sessink","year":"1994","journal-title":"Int. Arch. Occup. Environ. Health"},{"issue":"4","key":"10.1016\/j.jchromb.2022.123411_b0060","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1080\/00039896.1996.9936030","article-title":"Exposure of oncologic nurses to methotrexate in the treatment of osteosarcoma","volume":"51","author":"Mader","year":"1996","journal-title":"Arch. Environ. Health"},{"issue":"12","key":"10.1016\/j.jchromb.2022.123411_b0065","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1002\/rcm.2527","article-title":"Simultaneous determination of low levels of methotrexate and cyclophosphamide in human urine by micro liquid chromatography\/electrospray ionization tandem mass spectrometry","volume":"20","author":"Barbieri","year":"2006","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jchromb.2022.123411_b0070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jchromb.2016.10.021","article-title":"Highly sensitive LC-MS\/MS methods for urinary biological monitoring of occupational exposure to cyclophosphamide, ifosfamide, and methotrexate antineoplastic drugs and routine application","volume":"1038","author":"Canal-Raffin","year":"2016","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"issue":"1-3","key":"10.1016\/j.jchromb.2022.123411_b0075","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0378-4274(02)00163-7","article-title":"Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents","volume":"134","author":"Turci","year":"2002","journal-title":"Toxicol. Lett."},{"issue":"5","key":"10.1016\/j.jchromb.2022.123411_b0080","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/1078155216643860","article-title":"Pilot study of biological monitoring of four antineoplastic drugs among Canadian healthcare workers","volume":"23","author":"Poupeau","year":"2017","journal-title":"J Oncol Pharm Pract."},{"key":"10.1016\/j.jchromb.2022.123411_b0085","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jpba.2018.03.024","article-title":"A UHPLC-MS\/MS-based method for the simultaneous monitoring of eight antiblastic drugs in plasma and urine of exposed healthcare workers","volume":"154","author":"Izzo","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2022.123411_b0090","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4212\/cjhp.v72i1.2870","article-title":"Biological monitoring of 4 antineoplastic drugs in health care workers from 2 adult hospitals: a pilot study","volume":"72","author":"Chauchat","year":"2019","journal-title":"Can. J. Hosp. Pharm."},{"issue":"8","key":"10.1016\/j.jchromb.2022.123411_b0095","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1177\/1078155220907129","article-title":"Quantification of healthcare workers\u2019 exposure to cyclophosphamide, ifosfamide, methotrexate, and 5-fluorouracil by 24-h urine assay: a descriptive pilot study","volume":"26","author":"Palamini","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jchromb.2022.123411_b0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I","article-title":"The clinical pharmacology of methotrexate: new applications of an old drug","volume":"41","author":"Bleyer","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.jchromb.2022.123411_b0105","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/(SICI)1097-0231(20000215)14:3<173::AID-RCM862>3.0.CO;2-K","article-title":"Determination of methotrexate in human urine at trace levels by solid phase extraction and high-performance liquid chromatography\/tandem mass spectrometry","volume":"14","author":"Turci","year":"2000","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jchromb.2022.123411_b0110","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/bmc.3684","article-title":"Dispersive solid-phase extraction procedure coupled to UPLC-ESI-MS\/MS analysis for the simultaneous determination of thirteen cytotoxic drugs in human urine","volume":"30","author":"Fabrizi","year":"2016","journal-title":"Biomed. Chromatogr."},{"issue":"4","key":"10.1016\/j.jchromb.2022.123411_b0115","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1177\/1078155219870591","article-title":"Application of an innovative high-throughput liquid chromatography-tandem mass spectrometry method for simultaneous analysis of 18 hazardous drugs to rule out accidental acute chemotherapy exposures in health care workers","volume":"26","author":"Shu","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jchromb.2022.123411_b0120","doi-asserted-by":"crossref","first-page":"114345","DOI":"10.1016\/j.jpba.2021.114345","article-title":"Comparison of LC-MS3 and LC-MRM strategy for quantification of methotrexate in human plasma and its application in therapeutic drug monitoring","volume":"205","author":"Yin","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2022.123411_b0125","unstructured":"EMA, ICH guideline M10 on bioanalytical method validation and study sample analysis - Step5, European Medicines Agency, Amsterdam, The netherlands, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf (accessed July 27, 2022)."},{"key":"10.1016\/j.jchromb.2022.123411_b0130","unstructured":"EMEA, ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. Note for guidance on validation of analytical procedures: text and methodology, European Medicines Agency, London, 1995."},{"key":"10.1016\/j.jchromb.2022.123411_b0135","first-page":"387","article-title":"Occupational exposure to antineoplastic drugs: informations for biological monitoring","volume":"29","author":"Lepage","year":"2018","journal-title":"Toxicol. Anal. Clin."},{"issue":"17","key":"10.1016\/j.jchromb.2022.123411_b0140","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1039\/C8AN00479J","article-title":"Biomonitoring of occupational exposure to 5-FU by assaying \u03b1-fluoro-\u03b2-alanine in urine with a highly sensitive UHPLC-MS\/MS method","volume":"143","author":"Dhersin","year":"2018","journal-title":"Analyst."},{"key":"10.1016\/j.jchromb.2022.123411_b0145","doi-asserted-by":"crossref","first-page":"122305","DOI":"10.1016\/j.jchromb.2020.122305","article-title":"A highly sensitive UHPLC-MS\/MS method for urine biological monitoring of occupational exposure to anthracycline antineoplastic drugs and routine application","volume":"1156","author":"Villa","year":"2020","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023222003154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023222003154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:08:35Z","timestamp":1761606515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023222003154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":29,"alternative-id":["S1570023222003154"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2022.123411","relation":{},"ISSN":["1570-0232"],"issn-type":[{"type":"print","value":"1570-0232"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urine biomonitoring of occupational exposure to methotrexate using a highly sensitive UHPLC-MS\/MS method in MRM3 mode","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2022.123411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123411"}}